Neurocrine Biosciences receives Orphan Drug Designation for Valbenazine
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Subscribe To Our Newsletter & Stay Updated